Longevity is often framed as elite optimisation — cutting-edge diagnostics, expensive therapeutics, and biohacking experiments. In our conversation with Kristy Berry, CEO of Cenegenics, we took a different angle: what does mass market longevity look like? The discussion quickly shifted from lifespan to healthspan. The real goal is not living longer at any cost. It is living longer without chronic disease, disability, or cognitive decline. That distinction makes longevity practical rather than aspirational.
The science behind healthspan is not mysterious. Muscle mass predicts mortality. VO₂ max correlates strongly with cardiovascular risk. Insulin resistance precedes diabetes by years. Sleep affects hormonal regulation and inflammation. These variables are measurable and modifiable.
So why aren’t outcomes improving faster?
Because the primary constraint is behaviour, not biology. We already know what works: strength training, metabolic discipline, sleep hygiene, and regular screening. The challenge is sustained adherence. This is why longevity cannot be delivered as a pill or a single diagnostic test. It must be structured as a platform — combining data, coaching, accountability, and periodic reassessment. In other words, longevity must move from being a product to becoming infrastructure.
When we looked at this through an Indian lens, the urgency increased. Chronic diseases in India often appear nearly a decade earlier than in Western populations. That compresses the preventive window. If Western programs target individuals at 50, India may need to intervene in the early 30s. This has strategic implications. Longevity cannot remain a premium urban offering. It must be modular, scalable, and integrated into primary care. Otherwise, it risks widening health inequality.
Another key theme was data versus noise. Wearables and biomarker panels are generating unprecedented insights. But more data does not automatically mean better health. Without proper interpretation, constant monitoring can create anxiety rather than clarity. The real differentiator will not be who collects the most data, but who translates data into actionable, evidence-based decisions.
Trust will define this sector. Longevity interventions must be anchored in measurable outcomes: improved lipid profiles, preserved muscle mass, and enhanced cardiorespiratory fitness. Without rigour, the field risks drifting into over-promising. We also discussed who will drive adoption. While individuals are interested, employers and insurers may become the real accelerators. If preventive programs reduce long-term costs and productivity losses, institutional buyers could mainstream longevity faster than consumer demand alone. But this introduces an ethical challenge. If access is tied to income or corporate coverage, lifespan disparities could widen. Preventive medicine must not become a privilege.
Longevity is not about extending life indefinitely. It is about compressing morbidity — reducing the years lived with disease. The science is largely available. The tools are improving. The opportunity is significant. The real question is structural: can we design scalable, evidence-based systems that people actually sustain? If we succeed, longevity will not be a niche for the affluent. It will become a new baseline for how societies approach health — earlier, smarter, and more equitably.
